Endava and Velocity Partners Announce Merger to Become a Truly Global IT Player
Endava, a global technology company with a growing footprint in North America and Western Europe, today announced a merger with Velocity Partners, an innovative software development company with a strong presence in Latin America. This strategic move will expand technology services, scalability, geography, and capabilities to current and new clients on a global scale.
The resulting organisation will have over 4,600 people, and the additional six agile software development centres across Argentina, Uruguay, Venezuela, and Colombia will complement Endava’s existing delivery capability from centres across Romania, Moldova, Bulgaria, Serbia, Macedonia, and Colombia.
This will enable Endava, which provides agile, digital, and automation solutions to some of the world’s leading finance, insurance, telecommunications, media, technology, and retail companies, to further expand its footprint in North America and offer the world-class nearshore delivery model which has fuelled its success over the years. The company has a strong business performance with revenues up 38% year on year, supported by a mix of solid organic growth and acquisition-led international expansion.
Peter Stroeve, Managing Partner at Velocity Partners said: “We always aimed to be the nearshore Agile software leader, where talented people achieve their potential and clients gain a partner they trust. By becoming part of the Endava group, our clients will have access to an expanded set of solutions and services, while giving our staff access to new career paths, which will translate into new opportunities to work in global projects, as well as improved work environments and access to better training programmes.”
John Cotterell, Endava’s CEO said: “The Velocity team has distributed Agile in their DNA and an innovative approach, which will mean added capabilities to help our clients on their journey from idea to production and enable them to be more engaging, responsive, and efficient. We are building a global technology company and we are an aspirational brand for IT professionals in the regions in which we operate, attracting the best talent and offering great career and people development opportunities.”
ABOUT VELOCITY PARTNERS
Velocity Partners is an innovative global nearshore software development outsourcing company with over 12 years of experience delighting its clients and employees. The company offers high-value, high quality team augmentation solutions to companies of all sizes. Effective use of local talent in their development centres along with their deep roots in Lean and Agile processes allows Velocity Partners to provide a superior final product to all industries.
Velocity Partners has over 500 employees located in offices in North America and delivery centres located in Argentina, Uruguay, Colombia, and Venezuela.
Velocity Partners understands that employees are the key to success and it's important to meet their personal and professional needs. Teams are foundational to success at Velocity Partners. Through teamwork and collaboration their client success is achieved and there is a strong belief in leadership setting the vision and then empowering employees to work together towards one goal – customer success.
Endava is a privately-owned, global technology company, with over 17 years of experience of working with some of the world’s leading Finance, Insurance, Telecommunications, Media, Technology, and Retail companies. Through their Digital Evolution, Agile Transformation, and Automation solutions, Endava is helping clients be more engaging, responsive and efficient.
Endava has over 4,000 employees located in offices in North America and Western Europe and delivery centres in Colombia, Moldova, Romania, Macedonia, Serbia, and Bulgaria.
Along with investing in long term customer relationships, Endava recognised the importance of providing rewarding and challenging careers for people and, by doing so, has established itself as the employer of choice for the best and brightest engineers.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an